A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

NCT06260748 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Lack of feasibility

Conditions

Cerebrotendinous Xanthomatoses

Interventions

DRUG: Chenodeoxycholic acid
DRUG: Chenodeoxycholic acid Placebo

Sponsor

Leadiant Biosciences, Inc.